The Recovery of Biological Products conference is the leading international forum for the presentation and discussion of new insights and advances in the purification of biological products. Led by the American Chemical Society, Division of Biochemical Technology (BIOT), this international conference provides exposure to the latest developments in bioprocessing with a focus on downstream processing and aspects that affect the downstream steps. Unparalleled opportunities to network with industry leaders are a key feature of the conference. The RXXI conference will take place in April 2026 with approximately 260 attendees representing industry, academia and possibly government agencies such as the FDA. The conference will encompass topics such as harvest technology, mechanistic and mixed models, cell and gene therapy development and manufacturing, chromatographic separations, advances in vaccine development, and continuous unit operations. In addition to KIETS support, the conference organizers are inviting support from leading Biotechnology companies such as Abbvie, AGC Biologics, Solventum, Astellas, AstraZeneca, Bayer, Avitide, Biomarin, Bristol-Myers Squibb, Boehringer-Ingleheim, Amgen, Catalent, MilliporeSigma, Pall Life Sciences, Cytiva, Thermofisher, CSL, Eli Lilly, Merck, Pfizer, Biogen, Janssen/J&J, Just-Evotec, Lonza, Novo Nordisk, JSR Micro, Bio-Rad, Genentech/Roche, GSK, Gilead, Seattle Genetics, Sangamo, Novartis, Takeda, Regeneron, Sanofi, Samsung Biologics, and Vertex.
